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1INTRODUCTION
Over half a century ago researchers started to recognize the
association between obese population and the presence of hepatic
steatosis.1 Initially it was thought to be a relatively benign entity,  but
reports started emerging later which suggested that in some
circumstances fat in the liver could lead to cirrhosis or liver failure. This
was better elicited in patients who undergo surgical jejunoileal bypass for
morbid obesity.2
The histological features of “fatty liver disease” resemble alcohol-
induced liver injury, but because they occur in patients with little or no
alcohol consumption, the term Non alcoholic fatty liver disease (NAFLD)
was coined.3,4 NAFLD encompasses a spectrum of diseases that ranges
from bland hepatic steatosis, which is generally believed to be a benign
condition, to hepatic steatosis with a necroinflammatory component that
may or may not have associated fibrosis. This latter condition is termed
Non alcoholic steatohepatitis (NASH)4 and is considered the
‘progressive’ form of NAFLD.5
The natural history and progression of NASH to cirrhosis is
unclear with prevalence rates of 3% to 15% in case series6-8and small
2prospective cohorts have shown that NASH may progress to cirrhosis in
9% to 20% of patients.9-11
The pathogenesis of fatty liver disease and NASH is yet to be fully
elucidated, but the common association with visceral obesity,
hyperlipidemia, hypertension, and diabetes mellitus suggests that it is the
hepatic manifestation of the metabolic syndrome,12 with at least 1 of these
features present in over 90% of NAFLD patients.
In Europe and North America colon cancer is the second most
common cause of cancer death and is also one of the commonest causes
of cancer deaths throughout the worldwide. There are established risk
factors like old age, black race, low fiber diets and smoking. There are
some potential risk factors like insulin resistance and metabolic syndrome
as well. Metabolic syndrome is considered to be present when three of the
following parameters are present.
1. Increased waist circumference,
2. Hypertriglyceridemia (triglycerides ?150 mg/dl),
3. Low high-density lipoprotein
4. HDL cholesterol (?50 mg/dl in women and ?40 mg/dl in men),
5. Hypertension (130/ ?85 mmHg), and
6. Impaired fasting glucose.
3Metabolic syndrome is a sequel of conditions that has plagued the
world population. Its incidence is fast increasing in populations that are
obese and also in overweight people.
Both cardiovascular lesions and malignancies have a common risk
factor which is universal in prevalence. That common risk factor is
insulin resistance. The insulin resistance syndrome has five basic criteria.
They are hyperglycemia, visceral obesity, Hypertriglyceridemia, low
HDL-cholesterol level and hypertension. All these conditions are
individual risk factors for malignancies, and together they mean multiple
risks. Insulin resistance of various organs like liver, fatty tissues and
skeletal muscles causes reactive hyperinsulinemia, by the increased
secretory activity of the beta-cells. Insulin is a growth factor with diverse
metabolic effects. It predisposes to the increased production and
mitogenic activity of several insulin-like growth factors, and precipitates
pathological cell proliferation. Insulin resistance predisposes to
hyperglycemia.  Hyperglycemia appears promotes tumor genesis by
various pathways. The elevated serum glucose level is contributory to the
increased DNA synthesis of the tumor cells. Hyperglycemia leads to
production of free radicals and non glycation end products which are all
risk factors for the development of neoplasia.  Metabolic syndrome and
insulin resistance are associated with a higher risk of colon cancer. Non-
4alcoholic fatty liver disease (NAFLD) is regarded as a manifestation of
metabolic syndrome in the liver[11].
Though colorectal neoplasms are relativey rare in India when
compared with the western world, the incidence rate is on the rise due to
westernization. The low incidence of colorectal neoplasm in India is
thought to be because of the high fiber content of the diet which increases
the bulk of the stool thereby dramatically decreasing the intestinal transit
time. The rapid intestinal transit is proposed to be a favorable factor,
reducing the contact time between the carcinogenic substances present in
the stool and the intestinal lumen. However this concept is yet to be
proved scientifically.
Overall incidence of colorectal adenomas in people living in
tropical countries is much lower than the frequency with which the
colorectal adenomas are detected in the western population. However the
risk factors like obesity, insulin resistance and metabolic syndrome etc
are rising at a staggering rate in tropical countries. Especially in India the
metabolic syndrome is considered to be a new age epidemic affecting all
ages of population. Metabolic syndrome is considered to be the clinical
manifestation of insulin resistance. The insulin resistance is a risk factor
for colorectal adenomas.
5According to the epidemiological studies  colonic adenomas are
more common in patients who are obese, African American and with
positive family history of colon cancer, or diabetes mellitus. Newer
studies have shown that impaired glucose tolerance, dyslipidemia, and
metabolic syndrome are also associated with increased risk of colonic
adenomas. Patients with nonalcoholic fatty liver disease (NAFLD) often
share many of the previously mentioned risk factors for colonic
adenomas. We need more studies to assess the relationship between
NAFLD and colonic adenomas.
There are few studies from Europe, North America and East Asia
analyzing the incidence of colorectal adenomas in people with Non
alcoholic fatty liver. However such studies are lacking in India where the
incidence of both metabolic syndrome as well as non alcoholic fatty liver
disease is increasing. In this study we have compared the incidence rate
of colorectal adenomas in patients with Non alcoholic fatty liver with that
of patients without Non alcoholic fatty liver.
6REVIEW OF LITERATURE
Ludwig et al first coined the term NASH in 1980,[12]  Since  then
the prevalence of NAFLD has risen rapidly along with the rapid rise in
prevalence of obesity and diabetes.[13]  At  present  NAFLD  is  the  most
common cause of liver disease in the Western world.[14]  Non alcoholic
fatty liver disease represents a spectrum of diseases encompassing simple
steatosis to steatohepatits and fibrosis. Later on some patients with
NAFLD go on to develop cirrhosis.
In spite of recent advances, especially in elucidating the complex
metabolic and inflammatory pathways that lead to the development of
NAFLD, we lack knowledge about the exact pathogenesis of hepatic
steatosis and its progression to steatohepatitis and cirrhosis.[15,16] Steatosis
is found to be a condition with relatively  benign prognosis,[17] However it
may be associated with factors that are associated with progression to
more advanced, clinically relevant disease. Those factors are
inflammatory cytokines/adipokines, mitochondrial dysfunction and
oxidative stress.[18]
Insulin resistance is found to be the underlying cause of several
conditions like obesity, metabolic syndrome as well as NAFLD.
7Insulin resistance  leads to adipose tissue lipolysis, which causes
increased efflux of free fatty acids (FFA) from adipose tissue to the
liver.[19] Hyperinsulinaemia also promotes hepatic de novo lipogenesis,
which is markedly increased in NAFLD patients compared with normal
individuals.[20] It is now recognized that FFA promote insulin resistance,
inflammation and oxidative stress,[21,22] and thus rather than being
harmful, hepatic triglyceride accumulation may actually be protective by
preventing the harmful effects of FFA.[23] Oxidative stress mechanisms,
pro-inflammatory cytokines such as TNF alpha and interleukin 6, and
Adipokines such as Leptin (pro inflammatory and pro-fibrotic), and
Adiponectin (anti-inflammatory and insulin-sensitising) are also found to
be involved in promoting NASH.[16]
Only few percent of patients with NAFLD progresses to NASH
which means that there are several other factors which interplay along
with    underlying genetic predisposition.[15,18]
Causes of NAFLD
In most of the cases the NAFLD seem to occur in association with
conditions like insulin resistance, glucose intolerance or diabetes, central
obesity, dyslipidemia and hypertension. Thos with alcohol consumption
8greater than 20 gm per day are excluded from the diagnosis of NAFLD.
Other causes of steatosis are
1. Rapid weight loss
2.  Total parenteral nutrition,
3. Rare metabolic disorders
4.  Drug-induced Steatosis.
5. Hepatitis C, particularly genotype 3,
6. Endocrine disorders.
Epidemiology
In western adults prevalence of NAFLD ranges from 20% and
30%,[25,26] reaching upto 90% in the morbidly obese.[27] NASH,  has  an
estimated prevalence of 2–3% in the general population and 37% in the
morbidly obese.[27] NASH is much more clinically relevant than NAFLD.
NAFLD affects 3% of children, with a significant rise up to 53% in obese
children,[28,29] which can tremendously increase the  future disease
burden. 70% of type 2 diabetes population seems to have steatosis.[30]
Non-alcoholic fatty liver disease is prevalent in all races. However
it  seems  to  be  more  common  among  Hispanics  and  whites  when
9compared to African Amercian. This difference remains after controlling
for insulin resistance and obesity[25,31] and ethnic differences in lipid
metabolism is found to be the contributing factor.[25]
Pathogenesis
The pathogenesis of nonalcoholic fatty liver disease (NAFLD) is
multifactorial and its progression is related to several factors. The natural
history is influenced by both environmental and genetic factors.[32, 33]
In spite of the inadequate knowledge about the pathogenesis, a 2-
hit hypothesis is proposed,[34]
1.  First hit; An imbalance of fatty acid metabolism that leads to
hepatic triglyceride accumulation (steatosis).
2.   Second hit; Oxidative or metabolic stress and dysregulated
cytokine production.
This act sequentially, leading to subsequent inflammation and
fibrosis.
Hepatic mitochondrial dysfunction is very important in the
pathogenesis of NAFLD.[35]
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However, the 2-hit hypothesis was recently subjected to debate.
With the understanding of the deleterious effects of peripheral and
hepatic insulin resistance, the concept of multiple hits is being
considered. Despite lack of knowledge about specific pathways leading to
inflammation and fibrosis, there are evidences which seem to support a
role for dysregulated lipid partitioning which is proposed to be mediated
by insulin resistance leading to altered cytokine profiles.
Moreover, the capacity of the liver to repair and recover from
injury appears variable and this may change the rate of progression, and
also the severity of liver disease.[36]
Microscopic Features
The major histologic features of NAFLD resemble those of
alcohol-induced liver disease and include steatosis (fatty liver),
steatohepatitis (fatty liver plus parenchymal inflammation with or without
accompanying focal necrosis), and varying degrees of fibrosis, including
cirrhosis. Steatosis is predominantly macrovesicular and usually is
distributed diffusely throughout the liver lobule, although prominent
microvesicular steatosis and zone 3 (perivenular) steatosis have been
reported occasionally. Mild lymphocytic, neutrophilic, or mixed
11
inflammatory infiltrates also may be observed, and glycogenated nuclei
are common.
NASH, which is an advanced form of NAFLD, is indistinguishable
histologically from alcoholic hepatitis. The generally accepted minimal
criteria for the diagnosis of nonalcoholic steatohepatitis (NASH) are
steatosis, ballooning degeneration, and lobular inflammation.[37, 38]
Alternatively, portal inflammation may represent more progressive
disease, as shown by Brunt and colleagues.[40]   Steatosis is present in all
cases and can affect the hepatic lobules either diffusely or primarily in the
central zones. The degree of steatosis may correlate with the patient's
BMI and generally is more severe in NASH than in alcoholic hepatitis.
Lobular inflammation is a hallmark feature of NASH and is characterized
by infiltration of lymphocytes, other mononuclear cells, and
polymorphonuclear neutrophils. The intensity of the inflammation varies
with the severity of steatohepatitis and may be milder in NASH than in
alcoholic hepatitis. Glycogenated nuclei may be present. Hepatocyte
ballooning and hepatocyte necrosis of varying degrees are present and
may portend a worse prognosis. Mallory (or Mallory-Denk) bodies,
which may be small, sparse, and inconspicuous, are seen frequently. Mild
stainable iron may be present in up to 50% of the patients. Pericellular,
perisinusoidal, and periportal fibrosis has been described in 37% to 84%
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of patients with NASH. The extent of fibrosis varies considerably,
ranging from delicate strands surrounding small veins or groups of cells
to densely fibrotic septa with distortion of the hepatic architecture.
Perisinusoidal fibrosis is most common, especially in adults, is initially
mild, and predominates in zone 3 around the terminal hepatic veins.[41]
Cirrhosis is found on initial biopsy in 7% to 16% of patients with
NAFLD and abnormal liver biochemical test levels. The risk of cirrhosis
in the setting of NAFLD may be greatest in morbidly obese patients. In
NAFLD-associated cirrhosis, the typical histologic features of NAFLD
may be minimal or absent, potentially leading to the misdiagnosis of
cryptogenic cirrhosis.
Immunohistochemistry
p62 or ubiquitin immunostains are useful in NAFLD. Loss of
keratin 8/18 immunostaining  helps to identify Mallory denk bodies,
especially in patients with ballooned  hepatocytes and patients with
nonalcoholic steatohepatitis (NASH).  But, this is nonspecific and may
also be seen in patients with alcoholic steatohepatitis and patients with
cholestasis or ischemia41.
Clinical suspicion of NAFLD should be entertained in patients with
obesity, obstructive sleep apnea and diabetes mellitus. Other liver
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diseases that have to be ruled out before making a diagnosis of NAFLD
are listed below:
1. Viral hepatitides,
2. Excess alcohol consumption,
3.  Hemochromatosis,
4. Autoimmune hepatitis,
5. Wilson's disease
6. Alpha-1 antitrypsin deficiency,
7. Drug-induced liver injury.
Most of patients with NAFLD are asymptomatic and the condition
is suspected following elevated transaminases on routine testing. Hepatic
steatosis is a frequent incidental finding on ultrasound scan (USG)
performed during evaluation for conditions like suspected gallstone
disease. Right upper quadrant discomfort and fatigue are the two
commonest symptoms, although the latter may be present in Obstructive
sleep apnea (OSA). Hepatomegaly is common, with signs of chronic liver
disease being conspicuous by its absence. In a recent study it was found
that increased dorsocervical lipohypertrophy is associated with severity of
steatohepatitis among the anthropometric measures.
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Usually NAFLD is suspected in asymptomatic patients with
elevation in liver enzymes. However the entire spectrum of NAFLD can
present in patients with normal AST(aspartate amino tranferase) and
ALT(alanine amino transferase) levels.ALT levels are usually greater
than the AST levels. Alkaline phosphatase can be slightly elevated but is
rarely the only liver function test abnormality. Gamma-
glutamyltransferase (GGT) is increased frequently and can be a marker of
increased mortality.  Low albumin, hyperbilirubinaemia etc   may be
indicative of advanced liver disease and are not specific features of
NAFLD.
An elevated ferritin is seen in half of the patients and elevated
transferrin saturation in about 10%. However, these findings have no
correlation with elevated hepatic iron concentration, and its role in the
pathogenesis of NASH remains unclear.
Prediction of fatty liver in general population by ultrasound is done
using the Fatty Liver Index (FLI).[42]  An accuracy of 0.84 in detecting
fatty liver was achieved with FLI.[42] FLI has been commonly used by
several groups in population studies of NAFLD.[43–45] The commonly
used  test  in  patients  with  suspected  NAFLD,  with  steatosis  is  Ultra
sonogram (USG) which typically shows a hyperechogenic liver. A recent
15
study  which  compared  USG  with  the  liver  biopsy  in  235  patients  with
suspected fatty liver disease showed a sensitivity of 64% and specificity
of 97% for USG in patients with less than 30% steatosis, rising to 91%
and 93% respectively in patients with at least 30% steatosis.[46] However,
sensitivity and specificity of USG is reduced by morbid obesity.[47] and
also it is unable to quantify the amount of fat present or provide any
staging of disease,[48] and is operator-dependent with significant intra- and
inter-observer variability.[49]
Liver imaging
Liver imaging plays an important role in the clinical evaluation of
NAFLD and in epidemiologic studies of the disease. However,
conventional techniques are unable to grade or stage NASH and are
insensitive to hepatic fat that is less than 20% by weight. Cross-sectional
imaging is also used to assess fat distribution (visceral versus peripheral
fat) by determining the fat area at specific levels such as L4–5.
Ultrasonography detects steatosis by echogenicity and sound attenuation
with defined criteria . Ultrasonic elastography measures liver stiffness as
a marker of fibrosis. Sensitivity and specificity for stage 3–4 fibrosis is
91% and 75%, respectively (>7.9 kPa) but failure to acquire a signal
increases with a BMI of >30 kg/m2. Unenhanced computed tomography
16
(CT) relies on attenuation differences between the liver and spleen. A
“liver: spleen ratio” (in Hounsfield units) of <1 is consistent with
steatosis. Sensitivity and specificity for fatty liver were 84% and 99%,
respectively, for a spleen minus liver value of ?10 Hounsfield units in
one study. Conventional spin-echo magnetic resonance imaging (MRI) is
insensitive in detecting steatosis. However, refinements including “in–out
of phase imaging” improve fat detection. Improved signal processing
(using the Dixon technique) provides quantitative estimates expressed as
percentage triglyceride content. Magnetic resonance proton spectroscopy
is  the  most  accurate  means  of  quantifying  steatosis.  In  one  study,  the
correlation between fat measured in liver biopsies and proton
spectroscopy was 0.9 (P <0.001).
Role of liver biopsy
Liver biopsy remains the standard for confirming the diagnosis,
staging fibrosis, grading activity, and judging response to treatment.
Clinically, biopsy is often deferred until failure of a conservative course
of exercise and diet unless the evaluation indicates more advanced
disease or when there is a question of medication-induced injury.
Limitations and risks inherent to biopsy have led to study of noninvasive
“surrogate” markers.
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The limitations of biopsy include risk, patient inconvenience,
performance in obese patients, and sampling error. Although always
warranting careful caution, complications with liver biopsy are low and
available techniques offer improved safety. Sampling error is well
recognized with all types of liver biopsy and may represent regional
variation within the liver.
Metabolic syndrome and Insulin resistance
In 1988, Reaven described several risk factors like, dyslipidemia,
hypertension, hyperglycemia clustering together to form a clinical
syndrome. Syndrome X is the name given by him. Reaven and
subsequently others postulated that insulin resistance underlies Syndrome
X (hence the commonly used term insulin resistance syndrome).Later on
other researchers coined the term Metabolic syndrome to describe the
same entity which was endorsed by ADULT TREATMENT PANEL III
(ATP III).
This entity called as Metabolic syndrome predisposes to following
conditions namely
1. Cardiovascular Disease
2. Type 2 diabetes
18
3. Polycystic ovary syndrome,
4. Fatty liver,
5. Cholesterol gallstones,
6. Asthma,
7. Sleep disturbances
8. Some forms of cancer.
Components of Metabolic Syndrome
According to ATP III the following components of the metabolic
syndrome are related to CVD:
1.  Obesity which is predominantly abdominal
2. Dyslipidemia predisposing to atherogenic state
3.  Elevated blood pressure
4.  Impaired glucose intolerance
5.  Proinflammatory state
6.  Prothrombotic state
19
ATP III further classified the risk factor into underlying, major, and
emerging risk factors.
 Underlying risk factors are
1. obesity (especially
           abdominal obesity),
     2. Physical inactivity, and
     3. Atherogenic diet;
The major risk factors are
1. Cigarette smoking
2. Hypertension,
3. Elevated LDL cholesterol, low HDL cholesterol,
4. Family history of premature coronary heart disease (CHD),
5. Aging;
 The emerging risk factors are
1. Elevated triglycerides,
2. Small LDL particles,
3. Insulin resistance,
4. Glucose intolerance,
20
5. Proinflammatory state, and Prothrombotic state.
There are several criteria used for diagnosing metabolic syndrome like
ATP III guidelines, WHO guidelines, AACE clinical criteria etc
 Table 1.ATP III Guidelines for diagnosing Metabolic Syndrome (3 out of
5 risk factors needed
PATHOGENESIS OF METABOLIC SYDROME IN RELATION
TO INSULIN RESISTANCE
In the pathogenesis of metabolic syndrome insulin resistance seems
to play a more decisive role than obesity. Researchers claim that insulin
resistance, or its accomplice, hyperinsulinemia, predisposes to other
metabolic risk factors. However since insulin resistance is linked to
obesity it is difficult to evaluate the unique role of insulin resistance in
patients with metabolic syndrome.
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Though Insulin resistance rises with increasing body fat content, a
broad range of insulin sensitivities exists at any level of body fat. Most
people with categorical obesity (body mass index [BMI ?30 kg/m2) have
postprandial hyperinsulinemia and relatively low insulin sensitivity, but
variation in insulin sensitivities exists even within the obese population.
Spectrum of insulin sensitivities varies within patients who are
overweight (BMI 25 to 29.9 kg/m2), probably due to some inherited
component to insulin resistance.
In South Asians, especially Indians, insulin resistance occurs
commonly even with BMI ?25 kg/m2 and which probably contributes to
a high prevalence of  type 2 diabetes and premature CVD. This entity of
insulin resistance in only mild-to-moderate overweight people can termed
as primary insulin resistance.
Also in primary insulin resistance, weight gain leads to enhanced
insulin resistance and metabolic syndrome. Hence it is difficult to
dissociate obesity and primary insulin resistance in patients with
metabolic syndrome.
Hyperinsulinemia predisposes to enhanced release of very low-
density lipoprotein triglycerides, which will raise the serum triglycerides.
Insulin resistance in muscle leads to impaired glucose intolerance, which
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can be precipitated by increased hepatic gluconeogenesis. Finally, insulin
resistance may also elevate blood pressure by several mechanisms.
Colorectal adenomas
Colonic polyps may be divided into two major groups: neoplastic
(the adenomas and carcinomas) and non-neoplastic. The adenomas and
carcinomas share a characteristic—cellular dysplasia—but they may be
subdivided according to the relative contribution of certain microscopic
features. The non-neoplastic polyps may be grouped into several distinct
categories: hyperplastic polyps (including serrated polyps), “mucosal
polyps,” juvenile polyps, Peutz-Jeghers polyps, inflammatory polyps, and
others. Sub mucosal lesions also can impart a polypoid appearance to the
overlying mucosa and therefore are briefly mentioned even though they
are not true polyps.
Adenomatous polyps are tumors of benign neoplastic epithelium
that can either be pedunculated (i.e., attached by a stalk) or sessile (i.e.,
attached by a broad base with little or no stalk). The neoplastic nature of
adenomas is apparent by histological examination of their glandular
architecture. Tubular adenomas are the most common subgroup and are
characterized by a complex network of branching adenomatous glands. In
villous adenomas, the adenomatous glands extend straight down from the
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surface to the center of the polyp, thereby creating long, finger-like
projections. Tubulovillous (villoglandular) adenomas manifest a
combination of these two histological types.
A polyp is assigned a histological type on the basis of its
predominant glandular pattern, and in practice, pure villous adenomas are
quite rare. According to the World Health Organization, adenomas are
classified as tubular if at least 80% of the glands are of the branching,
tubule type and as villous if at least 80% of the glands are villiform. Of
all adenomatous polyps, tubular adenomas account for 80% to 86%,
tubulovillous for 8% to 16%, and villous adenomas for 3% to 16%.
Tubular adenomas usually are small and exhibit mild dysplasia, whereas
villous architecture is more often encountered in large adenomas and
tends to be associated with more severe degrees of dysplasia.
Adenomas are categorized into three size groups: less than 1 cm, 1
to 2 cm, and greater than 2 cm. Overall, most adenomas are smaller than
1 cm, but the size distribution of adenomas can vary greatly among
studies, depending on study design, age of the study population, and
location of the adenomas within the colon. Thus, in autopsy series, which
describe a presumably asymptomatic population dying of other causes,
only 13% to 16% of adenomas are larger than 1 cm, whereas surgical and
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colonoscopic series that include symptomatic or higher-risk patients
report a higher prevalence (26% to 40%) of adenomas larger than 1 cm.
In countries where the prevalence of colon cancer is high, adenomas tend
to be larger than in low-prevalence countries. Adenoma size increases as
a function of age, even in low-prevalence countries, and larger adenomas
are more common in distal colonic segments.
In Western countries, colonic polyps are usually adenomatous in
nature, are evenly distributed along the entire colon in asymptomatic
persons, and show a left-sided predominance in symptomatic patients.
There is dearth of such literature from India.
In Western society, the prevalence of adenomas shows a close
association with risk of development of colonic carcinoma. In Hawaiian
Japanese, who have a high risk for colonic malignancy, the prevalence of
adenomas is more than 50%.50 on contrast, Japanese people residing in
Japan have a low risk for colonic malignancy and polyps.50 India is
considered a low-prevalence region for colonic adenomas and colorectal
malignancy.51,52
Fewer than 5% of Indian adults with colonic carcinoma harbor
colonic adenomas.51
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In a retrospective study published by Jose tony et al in 2006 from
Calicut medical college, the incidence of colonic polyps in south Indian
population group was found to be around 5%. The predominant histology
of these polyps was adenoma and the most common site of polyp location
was found to be left colon. The study was an original article named “The
profile of colonic polyps in a south Indian population” published in
INDIAN JOURNAL OF GASTROENTEROLOGY at 2007.
The low incidence rate of colorectal polyps in Indian population
could be due to several factors including decreased genetic
predisposition, high dietary fiber intake, low rate of awareness among
public regarding the importance of screening colonoscopy, etc.
Although genetic predisposition clearly plays a role in colorectal
carcinogenesis, diet and life-style factors also contribute. It is estimated
that as much as a third to a half of colon cancer risk and a fourth to a third
of distal colon adenoma risk might be avoidable by modification of
dietary and life-style habits. For the most part, dietary factors that
correlate with a predisposition to colon cancer also are associated with a
risk for colonic adenomas. Factors that have each been correlated with an
increased adenoma risk include excess dietary fat, excess alcohol intake,
obesity, and cigarette smoking. Curiously, low calcium intake, despite
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being associated with increased risk for colon cancer, does not appear to
confer risk for adenoma (although calcium supplementation does seem to
lower adenoma recurrences).
A variety of clinical circumstances have been associated with
adenomatous polyps. Of the conditions discussed here, the predisposition
to have or to develop adenomas is strongest for ureterosigmoidostomy,
acromegaly, and Streptococcus bovis bacteremia. Patients with any of
these three conditions should undergo a thorough colorectal examination
and, in the former two conditions, periodic surveillance should be
considered (although the frequency of such examinations is not well
defined). As for the other conditions, either data are conflicting or the risk
is not strong enough to recommend a policy of surveillance.
Role of colonoscopy in detection of colorectal adenomas
Colonoscopy is preferred to double-contrast barium enema
examination for detecting adenomas because it has enhanced diagnostic
accuracy as well as therapeutic capability. This diagnostic superiority has
been demonstrated in studies of patients with known polyps as well as in
symptomatic patients who have negative findings on
proctosigmoidoscopic and barium enema examinations. Colonoscopy has
become the preferred colon cancer screening test in many settings.
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Despite its reputation as the gold standard for detecting adenomas,
colonoscopy does have some limitations. Colonoscopy fails to reach the
cecum in up to 10% of cases, it usually requires sedating the patient, and
it carries a higher cost than FOBT, FIT, or sigmoidoscopy. Colonoscopy
also can miss neoplasms, especially those located at flexures or behind
folds. In general, adenomas that are missed tend to be small. Studies
using a tandem colonoscopy design demonstrate adenoma miss rates of
0% to 6%, 12% to 13%, and 15% to 27% for adenomas larger than 1 cm,
between 6 and 9 mm, and less than 6 mm, respectively. CT colonography
reveals  that  colonoscopy can miss 12% to 17% of adenomas larger than
1 cm.
Given the concern about polyp miss rates, there has been
increasing attention to quality measures for colonoscopy. Key measures
of high-quality colonoscopy include adequacy of preparation, caecal
intubation rate, withdrawal time, and adenoma detection rate. Inadequate
preparation contributes to prolonged procedure times, decreased detection
of lesions, and the need for repeat colonoscopy before recommended
surveillance intervals. Colonoscopy is not considered complete unless
caecal intubation is accomplished. The majority of screening colonoscopy
studies reports a caecal intubation rate greater than 95%. Current
guidelines suggest that caecal intubation rates should be greater than 90%
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for all colonoscopies and greater than 95% in screening colonoscopies.
Most screening colonoscopy studies report adenoma detection rates of
25% to 40%. Men have been consistently found to have a higher burden
of adenomas than women. Current guidelines suggest that adenoma
detection rates should be at least 15% in women and 25% in men.
A key factor in adenoma detection rate is colonoscopic withdrawal
time. A large study examined the effect of withdrawal time in more than
7800 colonoscopies performed by 12 endoscopists. The adenoma
detection rate was 28.3% among endoscopists with a withdrawal time of
six minutes or more compared with 11.8% when the withdrawal time was
shorter than six minutes. The respective detection rates for advanced
adenomas were 6.4% and 2.6%; slower withdrawal time has been
validated by the same investigators in a follow-up study of over 2300
colonoscopies. Current recommendations suggest that a withdrawal time
of at least six minutes is necessary to maximize detection of adenomas.
Continued emphasis on adhering to quality measures and detailed
elucidation of the reasons lesions are missed can serve to improve
colonoscopy further.
Insulin resistance and metabolic syndrome are known risk factors
for colorectal adenomas. Non alcoholic fatty liver is a very common
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associated condition in patients with insulin resistance and metabolic
syndrome. There are few studies from western hemisphere trying to
assess the association between Non alcoholic fatty liver and colorectal
adenomas. Recently there have been some studies published from oriental
countries exploring the possibility of association between colorectal
adenoma and Non alcoholic fatty liver.
In  a  study  published  online  March  17  in  the  Journal  of  Internal
Medicine, the prevalence of early or precursor colorectal carcinoma
lesions are higher among patients with NAFLD who underwent screening
colonoscopy.
Andreas  Stadlmayr  et  al  evaluated  the  role  of  NAFLD  as  an
independent risk factor for CRC. In this retrospective study data
regarding 1,211 patients who underwent screening colonoscopy was
collected The study group consisted of 603 males and 608 females.
Average age of the study population was around 60 years. Increased
echogenicity on ultrasound examination was used as criteria to diagnose
NAFLD. Colorectal adenomas were categorized as tubular adenoma,
advanced adenoma, or carcinoma.
Overall 367 males and 265 females in that study were found to
have NAFLD. Significantly higher total rate of adenomas was present in
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men  and  women  who  had  NAFLD  than  individuals  without  NAFLD.
Among male patients with NAFLD there was an increased prevalence of
colorectal adenomas especially tubular adenomas as well as
adenocarcinomas. The commonest site was rectum. In female patients
with NAFLD there was an increased prevalence of colorectal adenomas
especially tubular adenomas and commonest site is proximal colon. The
difference between patients with normal ultrasonogram of liver and in
patients  with  NAFLD  after  adjusting  for  age,  race  and  other
comorbidities was significant (odds ratio, 1.47).
Hence the author concluded that patients with NAFLD when
undergoing screening colonoscopy have revealed significantly more CRC
precursor  lesions  and  early  CRC compared  to  patients  without  NAFLD.
So the author also suggests that detecting fatty liver on ultrasound should
make us think about referral to screening colonoscopy.
In a similar study published in the Journal of gastroenterology and
hepatology by Sang Tae Hwang et al, named as Relationship of Non-
alcoholic Fatty Liver Disease to Colorectal Adenomatous Polyps, the
authors concluded that the prevalence of NAFLD was 41.5% in the
adenomatous polyp group and 30.2% in the control group. By multiple
logistic  regression analysis,  NAFLD was found to be associated with an
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increased risk of colorectal adenomatous polyps (odds ratio, 1.28; 95%
confidence interval, 1.03–1.60). An increased risk for NAFLD was more
evident in patients with a greater number of adenomatous polyps.
However in a recent study named Prevalence of colonic adenomas
in patients with nonalcoholic fatty liver disease by Nadege T. Touzin et al
published in Therapeutic advances in gastroenterology in 2011,  have
given different conclusion from the previous studies.
It was a retrospective cohort observational study with study group
on 233 patients who underwent screening colonoscopies. The study was
from Brooke Army Medical Center. Data was collected from November
2007 to March 2010. The study group tried to assess for the association
between NAFLD and colonic adenomas.  Biopsy-proven simple steatosis
or nonalcoholic steatohepatitis (NASH) group were compared with a
control group without fatty liver disease on sonographic imaging.
Stratification was based on following parameters: race, body mass index
(BMI), gender, and family history. The outcome was adjusted for
variables which are known to be associated with increased risk of
adenoma.
In this analysis the mean age was 54.7±6.0 years.  Population
comprised of 62.7% White, and 18.5% Hispanic, slightly lesser
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population of blacks with 13.7%, African American, and 5.2% other. The
mean BMI was 29.7±5.8. The control group had prevalence of colonic
adenomas of around 25.1%. Around 24.4% patients in the NAFLD group
had colonic adenomas. (p value1.00). After adjusting for confounders
like, BMI, race and family history, no significant difference was found (p
value - 0.33). However, the ultrasound-negative patients ranked lower in
the number of adenomas per person (p value 0.016).
There was no difference in the prevalence of colonic adenomas
when comparing the NAFLD group who had undergone colonoscopy
with a group of control patients without NAFLD who had undergone
colonoscopy. However, patients with negative ultrasounds appeared to
have a lower polyp burden.
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AIM AND OBJECTIVES OF THE STUDY
1. To know the prevalence of colorectal adenomas in patients with
Non Alcoholic Fatty Liver Disease.
2.   To study the colonoscopy findings in patients with Non Alcoholic
Fatty Liver Disease.
3.  To  assess  the  risk  of  colorectal  adenomas  in  Patients  with  Non
Alcoholic Fatty Liver Disease and Metabolic syndrome
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MATERIALS AND METHODS
The study included out patients who attended the outpatient
department in our Institution (Department of Digestive Health and
Diseases, Government  Peripheral Hospital, Anna Nagar, Chennai -102)
which is a major tertiary care  Centre for liver diseases. Patients were
included in this study after their Willingness to undergo necessary
investigations. Informed written consent was  taken before the  enrolment
in this study. The period of study is from May 2011 to October 2011.
Inclusion criteria :  Age 40 -70 years.
                                         Patients with bright liver on ultrasound
examination Suggestive of fatty liver.
                                         Patients with normal liver on ultrasound
examination  as control group.
Exclusion criteria      :  Age below 40 years and above 70 years.
                                        Patients with Infectious,immunological,
hereditary, alcoholic liver diseases, Wilson
disease, Hemochromatosis, Patients with history
of colorectal malignancies, Family history of GI
polyposis, History of alcohol intake. Patients
with history of drug induced liver injury.
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Study methodology      :  Study is a Prospective case control study
                                       Population consist of patients   assessed in  the
institute satisfying the
                                       inclusion and exclusion criteria  during the period
from May 2011 to October 2011.
Study material            :  History
                                         Clinical features
                                         Investigations.
After careful screening for exclusion criteria 129 patients were
included in the study after obtaining informed consent. Patients who
came for master health checkup and healthy relatives of patients, with
normal liver on ultrasonogram and normal liver function tests were
included as control group after obtaining informed consent to undergo
screening colonoscopy.
Patients were examined clinically and their abdominal girth
measurements were taken midway between umbilicus and lower costal
margin. Blood pressure measured in sitting posture in both upper limbs.
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Obesity is defined as the presence of waist circumference more
than 40 inches in men and more than 35 inches in women according to
the ATP III guidelines of national cholesterol education program.
Presence of blood pressure more than 130mmHg systolic and
85mmHg diastolic was taken as significant as it forms a part of metabolic
syndrome according to the ATP III guidelines of national cholesterol
education program.
Presence of fasting blood glucose more than 110 mg% is
considered significant as it forms a part of metabolic syndrome according
to the ATP III guidelines of national cholesterol education program.
All patients were subjected to fasting lipid profile assessment.
Presence of fasting serum triglyceride more than 150mg% is considered
significant. Similarly presence of serum HDL values less than 40mg% for
men and less than 50mg% for women is considered significant as it forms
a part of metabolic syndrome according to the ATP III guidelines of
national cholesterol education program. Patients were diagnosed to have
metabolic syndrome if they satisfy the criteria for metabolic syndrome
according to ATP III guidelines of National Cholesterol Education
Program. According to this presence of any three of the five following
parameters is necessary to diagnose metabolic syndrome.
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1.  Fasting blood glucose ?110 mg%
2.  Waist circumference ?40 inches in men and ?35 inches in women.
3.  Blood pressure ?130mmHg systolic and ?85mmHg diastolic.
4.  Fasting serum triglyceride ?150mg%.
5.  Serum HDL values ?40mg% for men and ?50mg% for women.
All patients were subjected to screening ultra sonogram of
abdomen. Ultra sonogram was performed by a qualified and experienced
ultrasonologist.  Patients in whom echogenic bright liver was present in
the absence of viral, immunological, alcoholic and metabolic liver
diseases were presumed to have non alcoholic fatty liver. This method is
commonly used in clinical practice as well as in epidemiological studies
for diagnosing Non alcoholic fatty liver disease. The term Presumed
NAFLD is used in such studies to describe the condition.53
Those with normal echogenicity of liver in ultra sonogram and
satisfying the inclusion and exclusion criteria are included into control
group.
In patients with presumed Non alcoholic fatty liver disease with
coexisting elevation of transaminases like AST and ALT were subjected
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to liver biopsy after obtaining informed consent from the patients.
Histological grading of Non alcoholic liver disease in these patients was
carried out using the classification by matteoni et al54.
(1) simple steatosis     (2) steatosis with inflammation alone, (3) steatosis
with  inflammation and ballooning, and  (4) steatosis with inflammation
and fibrosis
After bowel preparation all these patients were subjected to
complete colonoscopy up to caecum. Careful screening for the presence
of polyps and neoplasia was done in all these patients. Biopsies were
taken from the polyps. The size of the polyps was noted as less than one
cm or greater  than one cm.  Site  of  the polyps as well  as  the number of
polyps were also noted.
Histopathological assessment of the biopsies taken from the polyps
was collected and the type of polyp is noted as whether hyperplastic,
inflammatory, hammartomatous or adenomatous polyps.
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STATISTICAL ANALYSIS
The  statistical  analysis  was  performed  with  the  Windows  SPSS
program ver. 15.0. The statistical results are presented as the mean ±
standard deviation or percentages. Statistical analyses included an
independent sample Student's t-test  and  the  ?2-test (for categorical
variables). The relationship of NAFLD with the presence of adenomatous
polyps was assessed by multiple logistic regression analysis after
adjustment for independent variables, including age, sex, hypertension,
diabetes, metabolic syndrome and NAFLD. Each odds ratio (OR) is
presented together with its 95% confidence interval (CI). P <  0.05  was
considered statistically significant.
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RESULTS
About 129 patients were included in this study. Age ranged from
40 year to 70 years. Average age of patients in this study was 54.77 years.
Table1. Age distribution in the study population.
N Minimum Maximum Mean
Std.
Deviation
Age in years 129 40 70 54.77 8.684
Valid N (listwise) 129
Among the study population 69 patients were found to have Non
alcoholic fatty liver and 60 patients were found to have normal liver
based on ultra sonogram abdomen and biochemical parameters. Patients
with Non alcoholic fatty liver comprised 53.5% of the study population.
Table2.   Number of NAFLD patients and control population
NAFLD
Frequen
cy Percent
Valid
Percent
Cumulati
ve
Percent
Abse
nt 60 46.5 46.5 46.5
Prese
nt 69 53.5 53.5 100.0
Total 129 100.0 100.0
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Among the study population the average age of control group was
56.13 years and the average age of NAFLD group was 53.58 years.
Table 3. Age distribution in NAFLD and CONTROL group
Patient
group N Mean
Std.
Deviation
Std.
Error
Mean
Age in
years
CONTROL 60 56.13 8.355 1.079
NAFLD 69 53.58 8.849 1.065
Among the study population 71 were men and 58   were women.
Table4. Sex distribution in the study population.
Freque
ncy Percent
Valid
Percent
Cumulative
Percent
Valid Male 71 55.0 55.0 55.0
Fema
le 58 45.0 45.0 100.0
Total 129 100.0 100.0
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Among the study population 51 patients   were diagnosed to have
metabolic syndrome which comprised about 39.5% of the study
population.
Table5. Distribution of metabolic syndrome in the study group.
Metabolic
syndrome Frequency Percent
Valid
Percent
Cumulative
Percent
Absent 78 60.5 60.5 60.5
Present 51 39.5 39.5 100.0
Total 129 100.0 100.0
Among the patients with NAFLD group 30 patients had metabolic
syndrome comprising about 43.5% of NAFLD group. Whereas in the
control group, metabolic syndrome was present in 21 patients comprising
about 35% of patients with control group.
Figure depicting the prevalence of metabolic syndrome in NAFLD
group and CONTROL group.
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Table6. Frequency of metabolic syndrome in NAFLD
and control groups
Metabolic
Syndrome Total
Absent Present
USG
FATTY
LIVER
ABSENT Count
39 21 60
 USG
65.0% 35.0% 100.0%
USG
FATTY
LIVER
% within
Metabolic
Syndrome
50.0% 41.2% 46.5%
PRESENT Count 39 30 69
% within
USG 56.5% 43.5% 100.0%
% within
Metabolic
Syndrome
50.0% 58.8% 53.5%
Total Count 78 51 129
% within
USG 60.5% 39.5% 100.0%
% within
Metabolic
Syndrome
100.0% 100.0% 100.0%
In the study population impaired fasting glucose was present in
48% of the patients.
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Table7. Frequency of impaired fasting glucose in study population.
Frequency Percent
Valid
Percent
Cumulative
Percent
Valid Absent 67 51.9 51.9 51.9
Present 62 48.1 48.1 100.0
Total 129 100.0 100.0
In the study population BP ?130/85 mm HG was present in 47.3%
population. There was no significant difference in NAFLD group and
control group.
Table8. Frequency of elevated BP in the study population.
BP? 130/85
mHG
Freque
ncy Percent
Valid
Percent
Cumulati
ve
Percent
Absent 68 52.7 52.7 52.7
Present 61 47.3 47.3 100.0
Total 129 100.0 100.0
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Among the study population hypertriglyceridemia was present in
31patients comprising about 24%. There was no significant difference in
NAFLD group and control group.
Table9. Frequency of Hypertryglyceridemia in study population
Hypertryglyc
eridemia Frequency Percent
Valid
Percent
Cumulative
Percent
Valid Absent 98 76.0 76.0 76.0
Present 31 24.0 24.0 100.0
Total 129 100.0 100.0
Among the study population 64(49.6%) patients had obesity based
on the waist circumference. There was no significant difference in
NAFLD group and control group.
Table10. Frequency of obesity in study population
obesity
Freque
ncy
Percen
t
Valid
Percent
Cumulative
Percent
Absent 65 50.4 50.4 50.4
Present 64 49.6 49.6 100.0
Total 129 100.0 100.0
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Among the study population 39(30.2%) patients had low HDL
cholesterol levels.
Table11. Frequency of low HDL cholesterol in study population.
Low HDL
cholesterol
Freque
ncy Percent
Valid
Percent
Cumulative
Percent
Valid Absent 90 69.8 69.8 69.8
Present 39 30.2 30.2 100.0
Total 129 100.0 100.0
Among the study population only four patients had elevation in
AST/ALT levels two folds above base line. All these four patients also
had fatty liver on ultrasonogram. Only these four patients were subjected
to liver biopsy after obtaining informed consent. In all other patients liver
biopsy could not be done due to ethical reasons.
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Table12. Frequency of elevated transaminases in study population.
Elevated
transaminases
Freque
ncy Percent
Valid
Percent
Cumulative
Percent
Valid Absent 125 96.9 96.9 96.9
Present 4 3.1 3.1 100.0
Total 129 100.0 100.0
Histological assessment of the liver biopsy specimen was done and
staging was done in four patients. None of them had cirrhosis while two
patients had steatosis with non specific lobular inflammation. Two
patients had steatosis with lobular inflammation and fibrosis.
In all the patients screening colonoscopy up to cecum was
successfully completed without any complications and careful screening
for the presence of any polyps was done. In the presence of any polyp the
size of the polyp, number of polyps and the location of polyps are noted.
In the study population 11 patients were found to have polyps in
the screening colonoscopy which formed about 8.5% of the study
population. Rest of the patients did not have any significant finding in the
colonoscopy.
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Table13. Frequency of polyps on colonoscopy in the
study population.
POLYP Frequency Percent
Valid
Percent
Cumulative
Percent
Absent 118 91.5 91.5 91.5
Present 11 8.5 8.5 100.0
Total 129 100.0 100.0
Among the 11 patients one patient had three polyps and three
patients had 2 polyps each and rest of them had one polyp.
Table14. Polyp burden in the study population.
Number of
polyps Frequency Percent
Valid
Percent
Cumulative
Percent
0 118 91.5 91.5 91.5
1 7 5.4 5.4 96.9
2 3 2.3 2.3 99.2
3 1 .8 .8 100.0
Total 129 100.0 100.0
Over all the distribution of polyps was predominantly on the left
colon.
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Table15. Location of polyps
Location of
polyps Frequency Percent
Valid
Percent
Cumulative
Percent
NO
POLYP 122 94.6 94.6 94.6
LEFT
COLON 6 4.7 4.7 99.2
RT
COLON 1 .8 .8 100.0
Total
129 100.0 100.0
In patients  with NAFLD the polyps were present  in 8.7% patients
and in control group it was 8.3%. This difference was not statistically
significant.
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Table16. Prevalence of polyps in NAFLD group and
CONTROL group.
polyp Total
Absent Present
Presumed
NAFLD
Absent Count 55 5 60
% within
USG 91.7% 8.3% 100.0%
% within
COLONO
SCOPY
46.6% 45.5% 46.5%
Present Count 63 6 69
% within
USG 91.3% 8.7% 100.0%
% within
COLONO
SCOPY
53.4% 54.5% 53.5%
Total Count 118 11 129
% within
USG 91.5% 8.5% 100.0%
% within
COLONO
SCOPY
100.0% 100.0% 100.0%
In  all  these  patients  biopsy  from  the  polyp  was  taken  and  histo
pathological assessment of polyps was done. Nine out of the 11 patients
were found to have tubular adenomas with no dysplasia and two patients
were found to have hyperplastic polyps. The frequency of adenomas in
the study population was about 7%.
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Table17. Histopathology of polyps in the study population.
Polyp
histology Frequency Percent
Valid
Percent
Cumulative
Percent
Absent 118 91.5 91.5 91.5
Adeno
ma
9 7.0 7.0 98.4
Others 2 1.6 1.6 100.0
Total 129 100.0 100.0
Among the study group the prevalence of adenoma in NAFLD
group was around 7.2% and in control population the prevalence was
about 6.8%. There was no statistically significant difference in the
prevalence of colonic adenomas in both the groups.
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Figure showing the number of adenomas in NAFLD and
CONTROL groups
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Table18. Prevalence of adenomas in NAFLD and CONTROL group
POLYP HPE Total
Absent
Adeom
a Others
USG
BRIGHT
LIVER
Absent
(CONTRO
L)
Count
55 4 1 60
% within
USG 91.7% 6.7% 1.7% 100.0%
% within
POLYP
HPE
46.6% 44.4% 50.0% 46.5%
Present
(NAFLD)
Count
63 5 1 69
% within
USG 91.3% 7.2% 1.4% 100.0%
% within
POLYP
HPE
53.4% 55.6% 50.0% 53.5%
Total Count 118 9 2 129
% within
USG 91.5% 7.0% 1.6% 100.0%
% within
POLYP
HPE
100.0% 100.0% 100.0% 100.0%
Among the patients with adenoma the average age was 60.44 years
around 6 years greater than those without adenomas. The age difference
was statistically significant (P value 0.037), based on t- test for equality
of means.
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Table19. Age distribution in patients with and with out adenomas.
ADENO
MA N Mean
Std.
Deviation
Std.
Error
Mean
Age in years Absent 118 54.21 8.660 .797
Present 9 60.44 6.616 2.205
Among the study group the prevalence of colorectal adenoma was
more common among patients with metabolic syndrome than others and
the difference was statistically significant. All the patients with colorectal
adenomas also had metabolic syndrome.(p value 0.047)
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Table20. Colorectal adenomas in patients with and without
metabolic syndrome.
POLYP HPE Total
Absent
Adeno
ma Others
Metabolic
Syndrome
Absent Count 76 0 2 78
% within
Metabolic
Syndrome
97.4% .0% 2.6% 100.0%
% within
POLYP
HPE
64.4% .0% 100.0% 60.5%
Present Count 42 9 0 51
% within
Metabolic
Syndrome
82.4% 17.6% .0% 100.0%
% within
POLYP
HPE
35.6% 100.0% .0% 39.5%
Total Count 118 9 2 129
% within
Metabolic
Syndrome
91.5% 7.0% 1.6% 100.0%
% within
POLYP
HPE
100.0% 100.0% 100.0% 100.0%
The colorectal adenoma burden was found to be higher in the
NAFLD group when compared with control group.
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There was a statistically significant increase in the adenoma burden
in patients with NAFLD group compared with the control group based on
t- test for equality of means. P value (0.027).
Table21. Adenoma burden in relation to presumed NAFLD
USG N Mean
Std.
Deviation
Std.
Error
Mean
No. of
polyps
Absent 4 1.00 .000 .000
Present 5 2.00 .707 .316
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DISCUSSION
Non alcoholic fatty liver is a new age epidemic which has started to
rise in incidence for last two decades. NAFLD which is a hepatic
manifestation of metabolic syndrome and metabolic syndrome seems to
increase the risk of colorectal cancer, as shown in studies [Colangelo et
al. 2002; Trevisan et al. 2001]. Insulin resistance is the common under
lying mechanism for both entities [Pais et al. 2009]. Perhaps the same
factors that lead to metabolic syndrome, also has a distinct role in
carcinogenesis55.
Adiponectin is decreased in obese and diabetics or in patients with
insulin resistance. This leads to increased insulin levels due to marked
insulin resistance, which in turn causes increase in insulin growth factor-1
(IGF-1) [Kaaks et al. 2000]. Adiponectin inhibits tumor necrosis factor
alpha (TNF-a), which plays a role in tumor cell proliferation and
angiogenesis [Ferroni et al. 2007; Rose et al. 2004].
In  a  study  by  Ferroni  and  colleagues  [Ferroni  et  al.  2007],  there
was an inverse association between adiponectin levels to colonic tumor
stage and adiponectin levels independently seem to predict cancer
recurrence [Stattinet al. 2004]. Insulin binds to IGF-1 receptors and as
very important role in  modifying cell proliferation, apoptosis and  also
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increased levels of vascular endothelial growth factor, an angiogenic
factor,  that supports cancer growth [Grimberg and Cohen, 2000; Warren
et al. 1996].
Although we need more studies to find out how exactly the risk of
colorectal adenomas is increased in patients with metabolic syndrome, an
association is somewhat obvious and clinically recognizable55.
There are several studies from western literature analyzing the
prevalence of colorectal adenomas in patients with Non alcoholic fatty
liver disease. Some of them have found an increased prevalence of
colorectal adenomas in patients with Non alcoholic liver disease leading
to the suggestion that patients with Non alcoholic fatty liver disease
should be considered for screening colonoscopy.
In the study by Sang Tae Hwang et  al,  the prevalence of  NAFLD
was 41.5% in the adenomatous polyp group and 30.2% in the control
group. By multiple logistic regression analysis, NAFLD was found to be
associated with an increased risk of colorectal adenomatous polyps (odds
ratio, 1.28; 95% confidence interval, 1.03–1.60). An increased risk for
NAFLD was more evident in patients with a greater number of
adenomatous polyps. 56
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In a similar study by Stadlmayr A et al, the author concluded that
Patients with NAFLD had significantly more CRC precursor lesions and
early CRC. This elevated risk is independent from other manifestations of
Insulin Resistance. These findings seem to favor referral to screening
colonoscopy in patients with NAFLD.57
However many other studies performed at different centers later
seem  to  show  results  that  are  different  from  the  previously  discussed
studies.  In a study by Wong et al, the prevalence of colorectal adenomas
is equal in patients with non alcoholic fatty liver and control group. The
prevalence was slightly higher in patients with non alcoholic
steatohepatitis patients.
The author concluded a high prevalence of colorectal adenomas
and advanced neoplasms is associated with non alcoholic steatohepatitis.
The right sided colon is a more common site for adenomas. Colorectal
cancer screening is strongly indicated in this high risk group. After
demographic and metabolic factors were adjusted, non-alcoholic
steatohepatitis still  remained a significant factor in increased incidence of
adenomas (adjusted OR 4.89, 95% CI 2.04 to 11.70) and advanced
neoplasms (OR 5.34, 95% CI 1.92 to 14.84). However, the prevalence of
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adenomas and advanced neoplasms was not different in patients with
simple steatosis and control subjects.58
In a study by Nadege Touzin et al, the author found out that the
prevalence of adenomas in both NAFLD group and control was similar.
25.1% of patients in control group had colorectal adenomas and where as
it was 24.4% in the NAFLD group including simple steatosis and NASH
(p value 1.00). After adjusting for known confounders like, BMI, race
and family history, not much significant difference (p value 0.33) could
be found. However, the ultrasound-negative patients had fewer adenomas
per person (p value 0.016). So in this study, the prevalence of colonic
adenomas in the NAFLD group and in the control patients without
NAFLD was not significantly different. However, patients with negative
ultrasounds appeared to have a lower polyp burden.55
The increased risk of colorectal adenomas in patients with
metabolic syndrome was described by Giovannucci E in a review article
named Metabolic syndrome, hyperinsulinemia, and colon cancer: a
review.59
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In India there is no study to analyze the association between non
alcoholic fatty liver and colorectal adenomas. In this study the prevalence
of colorectal adenoma in patients with non alcoholic fatty liver disease
and normal population was assessed. In this case controlled study the
prevalence of colorectal adenoma over all was around 7%. The
prevalence of colorectal adenoma in patients with presumed non
alcoholic fatty liver group was around 7.2% and on control group it was
around 6.8%.  The difference was not statistically significant.
However the polyp burden in patients with presumed non alcoholic
fatty liver is twice that of the control group with p value of 0.027. In
patients with non alcoholic fatty liver disease group the number of polyps
is 2 and above where as in control group usually the number of polyp is
one.
Irrespective of the presence or absence of fatty liver, the patients
with colorectal adenoma had metabolic syndrome. Metabolic syndrome
seems to be the strong risk factor of colorectal adenoma.
Average  age  of  patients  with  colorectal  adenoma  in  this  study  is
about 60.5 years, which is 6 years greater than the average age of patients
without colorectal adenoma.
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In this study age and metabolic syndrome are the independent risk
factors for colorectal adenomas where as non alcoholic fatty liver disease
is not an independent risk factor.  Non alcoholic fatty liver seems to
increase the polyp burden in patients with colorectal adenomas.
The limitations in this study are small sample size of the study
population and the lack of histological diagnosis and grading of fatty
liver. The diagnosis of non alcoholic fatty liver was made based on the
presence of bright liver on ultrasound with absence of evidence for any
other liver disease or systemic disease predisposing to fatty liver. Since
the ultrasound has poor sensitivity to detect fatty liver in obese patients,
this could impair the study outcome. Liver biopsy could not be performed
in  all  patients  because  of  ethical  reasons.  Liver  biopsy  was  done  in  our
patients in whom there was an elevation in the AST/ALT levels. In these
patients two had steatohepatitis and two had fibrosis. However in these
patients there was no colorectal adenomas and hence the histology does
not seem to be a factor in prevalence of colorectal adenoma.
Over all prevalence of colorectal adenoma in this study population
was around 7% which is slightly higher than what was found in previous
studies.  This  could  probably  due  to  the  fact  that  the  average  age  of
patients in the study population was 54.77% and patients belonged to
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urban population. In an article published by Jose Tony et al, the
prevalence of polyps was around 5.1% most of them being adenoma. This
article titled “Profile of colonic polyps in a southern Indian population”
was published in Indian Journal of Gastroenterology 2007 Vol 26 May -
June 129.
The relationship between metabolic syndrome and colorectal
neoplasia is well established and the underlying reason for this has been
increased insulin resistance in patients with metabolic syndrome.
Metabolic syndrome is a manifestation of insulin resistance which
predisposes to several malignancies. In this study all the patients who
were diagnosed to have colorectal adenoma also had metabolic syndrome.
There was a statistically significant association between colorectal
adenoma and metabolic syndrome.(p value 0.04)
Age of patients in this study also showed statistically significant
difference among the patients with colorectal adenoma and patients
without colorectal adenoma. The average age of patients with colorectal
adenoma was about 60.55 years which was 6 years greater than the
average age of rest of the study group.
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CONCLUSIONS
1. Non alcoholic fatty liver disease is not an independent risk factor
for colorectal adenomas.
2. Non alcoholic fatty liver disease may increase the polyp burden in
patients with colorectal adenomas.
3. Metabolic syndrome increases the risk of colorectal adenoma
irrespective of the presence or absence of Non alcoholic fatty liver.
4. Screening colonoscopy is advisable in patients with Metabolic
syndrome.
5. Colorectal adenomas seem to occur after the age of 60 years.
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